Press Release

Data presented today at the 8th European Congress on Menopause (EMAS) demonstrated that the majority of osteoporosis patients treated with EVISTA® (raloxifene) stay on therapy for the first two years.

300 postmenopausal osteoporosis patients received oral treatment with EVISTA®. Patients were considered compliant if they had taken at least 80% of their medication. 1 Prof. Dr. P. Hadji, University Hospital of Giessen and Marburg GmbH, Marburg, Germany, said that “Results show that at 12, 24 and 36 months 96.4 %, 80.5% and 62% respectively of patients remained on therapy. The mean MPR was 52.8%. Finally 38.5% of all patients were classified adherent”.

The treatment of osteoporosis among postmenopausal women represents a major public health challenge because long-term therapy is required to prevent fractures and chronic disability.2 Today’s results highlight the importance of good treatment compliance to help achieve therapeutic benefits for patients, and reduce the burden that osteoporosis places on individuals and the healthcare system.3

“Poor adherence has a negative effect on patient outcomes, and current treatment with many osteoporosis therapies tends to be suboptimal,” comments Prof. Dr. P. Hadji, “However, EVISTA® has a long and proven history of patient compliance. Years of research not only confirm that patients adhere to treatment regimens with the drug, but also demonstrate a safety profile that is as strong now as it was when EVISTA® first came to market.”

The data released today at EMAS comes in advance of EVISTA®’s 10th anniversary, a turning point that will not go unmarked. Coinciding with World Osteoporosis Day this October, plans are already underway to highlight EVISTA®’s continued success as a treatment for postmenopausal women with osteoporosis. Reinhard Bauer, CEO of DAIICHI SANKYO EUROPE, says “DAIICHI SANKYO is delighted to mark the 10th anniversary of EVISTA® later this year. The anniversary is intended to raise awareness of the disease and highlight the role that EVISTA® has played in transforming osteoporosis management over the years.”

For more information:
http://www.daiichi-sankyo.eu/site_eu/?node_id=2715